NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Duke University
UNICANCER
Dana-Farber Cancer Institute
Seagen Inc.
Sun Yat-sen University
US Oncology Research
Second Affiliated Hospital, School of Medicine, Zhejiang University
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Angiochem Inc